Results 251 to 260 of about 174,356 (352)

Dual targeting of BRAF^V600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress. [PDF]

J Exp Clin Cancer Res
Hu J, Ghosh C, Khaket TP, Yang Z, Tabdili Y, Alamaw ED, Boufraqech M, Dixon SJ, Kebebew E.   +8 more
europepmc   +1 more source

POLARIS: encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis

Alexander M. Menzies, Michael A. Davies
openalex   +2 more sources

Extracellular vesicles released from melanoma cells constitutively expressing MHC class II promote immune evasion and cancer progression

The FEBS Journal, EarlyView.
Here, we report the role of extracellular vesicles (EVs) released from melanoma cells constitutively expressing MHC class II in the regulation of immune cell functions and melanoma metastasis. In particular, we observed an increased localization of HLA‐DRα, CAM receptors, PD‐L1, and STAT3 signaling proteins in the EVs.
Francesca Costantini, Caterina Di Sano, Samuele Raccosta, Mauro Manno, Giovanna Barbieri   +4 more
wiley   +1 more source

Integrating TBSRTC subcategorization and <i>BRAF</i> V600E testing for precision management of Bethesda III thyroid nodules: a WHO 5th edition-based study highlighting subtype-specific diagnostic disparities. [PDF]

Front Oncol
Yu Q, Yang Z.
europepmc   +1 more source

DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset

, 2010
Marianne Berg, Stine A. Danielsen, Terje Ahlquist, Marianne A. Merok, Trude H. Ågesen, Morten H. Vatn, Tom Mala, O. Sjö, Arne Bakka, Ingvild Moberg, Torunn Fetveit, Øystein Mathisen, Anders Husby, Oddvar M. Sandvik, Arild Nesbakken, Espen Thiis‐Evensen, Ragnhild A. Lothe   +16 more
openalex   +2 more sources

Molecular pathology of phyllodes tumours of the breast—much more than MED12

Histopathology, EarlyView.
Phyllodes tumours can develop from fibroadenomas bearing MED12 variants by the development of pTERT alterations (“MED12 pathway”) or de novo (“MED12 independent pathway”). Grade progression is associated with increasing genetic complexity including cancer driver gene aberrations. Molecular alterations can be useful in assigning grade and distinguishing
Jia‐Min B Pang, Kylie L Gorringe, Puay Hoon Tan, Stephen B Fox   +3 more
wiley   +1 more source

Malignant Melanoma: Landscape of Molecular Markers. [PDF]

Biomedicines
Winter M, Ebner S, Baum V, Kiil K, Rauschendorf MA, Wild PJ.   +5 more
europepmc   +1 more source

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source

Survival impact of second primary cutaneous and non‐cutaneous melanoma in melanoma survivors

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this US population‐based cohort study, melanoma survivors diagnosed with regional/distant‐stage SPCM or SPNCM had worse survival compared to those with a single melanoma. Abstract Background Melanoma survivors have a high risk of developing second primary neoplasms, both cutaneous melanoma (SPCM) and non‐cutaneous melanoma (SPNCM), but little is ...
Jingjing Xie, Maija Kiuru, Brad H. Pollock, Theresa H. M. Keegan   +3 more
wiley   +1 more source